Analysts Are Bullish on These Healthcare Stocks: MariMed (MRMD), Trevi Therapeutics (TRVI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MariMed (MRMD – Research Report) and Trevi Therapeutics (TRVI – Research Report) with bullish sentiments.
MariMed (MRMD)
Echelon Wealth Partners analyst Andrew Semple reiterated a Buy rating on MariMed today and set a price target of $0.40. The company’s shares closed last Thursday at $0.28.
According to TipRanks.com, Semple is a 1-star analyst with an average return of -2.2% and a 31.3% success rate. Semple covers the Healthcare sector, focusing on stocks such as Ascend Wellness Holdings LLC, Cannabist Company Holdings, and Decibel Cannabis Company.
Currently, the analyst consensus on MariMed is a Moderate Buy with an average price target of $0.40.
See Insiders’ Hot Stocks on TipRanks >>
Trevi Therapeutics (TRVI)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Trevi Therapeutics today and set a price target of $6.00. The company’s shares closed last Thursday at $2.99.
According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.1% and a 23.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Cognition Therapeutics, and Denali Therapeutics.
Trevi Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.40, a 179.2% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRMD: